Formononetin mitigates atherosclerosis by reducing Trimethylamine N-oxide production through modulating gut microbiota in LDLR-/- mice
Published: 14 February 2025| Version 1 | DOI: 10.17632/wcbpgcgbnc.1
Contributor:
Guobin ZhengDescription
Our results suggest formononetin reduces TMAO production by modulating gut microbiota, thus contributing to the anti-atherosclerotic effect.
Files
Categories
Pharmacology